当前，全球经济形势不断变化，各项挑战相互交织。与此同时，人工智能（AI）等带来的技术变革层 出不穷，变局之中亦有机遇。在此背景下召开的世界经济论坛第十六届新领军者年会（以下简称"2025 夏季达沃斯论坛"）聚焦重要的新兴市场，并重点关注中国，探讨新时代的企业家精神和新兴技术如何 助力释放全球增长新动力。 6月24日是2025夏季达沃斯论坛首日。当天，世界经济论坛执行董事萨迪娅·扎希迪（Saadia Zahidi）接 受证券时报记者专访。扎希迪在采访中强调了合作共赢与新兴技术对于全球经济复苏的重要意义，指出 中国仍在持续发挥全球经济增长中的"稳定器"作用，同时呼吁各国将目光重新聚集于可持续发展目标。 证券时报记者：当前全球经济面临通胀压力、供应链重构、地缘冲突等多重挑战，您认为2025年全球经 济复苏的核心驱动力是什么？ 证券时报记者贺觉渊韩忠楠 从中国的转型经验看，扩大国内需求显然重要。目前，中国更加积极的财政政策和适度宽松的货币政策 正在持续发挥作用。根据世界经济论坛首席经济学家展望，未来中国或将出台更有力度的财政和货币政 策来扩大国内需求。 证券时报记者：中国正推进"双循环"与高质量发展，您如何看待中国经 ...

金十数据6月24日讯，贝莱德认为，在中国的生物技术、自动化和自动驾驶领域可能会出现更多类似 DeepSeek的时刻，反映其对中国人工智能领域进一步发展的乐观态度。贝莱德大中华区投资策略师陆 文杰在周二的发布会上表示，很难给出确切的时间，但目前的环境适合这些科技公司实现非常强劲的创 新。 贝莱德：预计中国科技行业将出现更多DeepSeek时刻 ...

Core Viewpoint - The company emphasizes the importance of long-term adaptability and global investment strategies in the face of significant market changes, leveraging technology and expanding into international markets [1][2]. Group 1: Investment Strategy - The company has restructured its investment system using artificial intelligence technology, named "AI Cybertron," and has expanded its investment scope to include markets in South Korea, India, and Singapore [1]. - The investment portfolio currently includes high-quality companies from A-shares, Hong Kong stocks, U.S. stocks, and other international markets, reflecting a global investment approach [2]. - The core research team consists of seven members, with five being overseas returnees, enhancing the team's global research capabilities [2]. Group 2: Focus Areas - The company is particularly optimistic about the technology sector, especially artificial intelligence, and plans to build a global investment portfolio centered around AI [4]. - Investment in the technology sector is categorized into scientific technology and business innovation, with a focus on areas such as AI computing, autonomous driving, and quantum computing [4]. - In business innovation, the company is looking at investment opportunities in SaaS, fintech, and platform economy sectors driven by AI technology [5]. Group 3: Investment Philosophy - The company adheres to value investing principles but recognizes the need for flexibility in adjusting positions based on market sentiment and using derivative tools to enhance portfolio stability [3]. - The selection criteria for investment targets include strong competitiveness, high growth potential, and significant value creation [3]. - The company aims to create absolute returns for investors by exploring derivative tools to improve position adjustment flexibility and enhance portfolio resilience [3].

Summary of Key Points Core Viewpoint The article provides an overview of the recent activities in the Hong Kong stock market, highlighting the number of companies that have submitted applications for listing, those that have passed the hearing, and details about their financial performance and market positions. Group 1: New Applications - A total of 19 companies submitted applications to the Hong Kong Stock Exchange from June 16 to June 22 [3] - New Hope Group (600803.SH) is the largest private natural gas company in China, with a market share of approximately 6.1% in 2024 [3] - Wolong Technology (002130.SZ) is the second-largest high-speed copper cable manufacturer globally, holding a 24.9% market share [4] - Beijing Geekplus Technology Co., Ltd. is the largest provider of AMR solutions globally, maintaining its leading position for six consecutive years [5] - Banu International Holdings is the largest hot pot brand in China by revenue, with a market share of 3.1% [6] - Hope Sea Inc. is the largest comprehensive electronic product import supply chain solution provider in China, with an import GMV of approximately RMB 34.8 billion in 2024 [7] - Guangzhou Shiyuan Electronic Technology Co., Ltd. ranks first in the Chinese market for interactive smart panels with a 25.0% market share [8] - Anmai Biotechnology Co., Ltd. ranks second globally in T-cell connector therapy, with total transaction values exceeding USD 2.1 billion [9] - Beijing Haizhi Technology Group focuses on industrial-grade AI solutions, ranking fifth in the Chinese market [10] - Suzhou Jiyi Technology Co., Ltd. ranks second in digital retail operations in China [11] - Drip Irrigation International Investment Co., Ltd. is the first global exchange group based on revenue-sharing models [12] - Zhaowei Electromechanical (003021.SZ) provides integrated micro-drive systems, with revenues projected to grow [13] - Meige Intelligent (002881.SZ) ranks fourth globally in wireless communication modules, holding a 6.4% market share [14] - Yuxin Technology (300674.SZ) is a leading fintech solution provider in China, with significant market shares in various sectors [15] - Shanghai Zhuoyue Ruixin Digital Technology Co., Ltd. ranks second in the digital education market for higher education in China [16] - Zhaoyi Innovation (603986.SH) is the second-largest NOR Flash provider globally, with an 18.5% market share [17] - Changchun Changguang Chenxin Microelectronics Co., Ltd. specializes in high-performance CMOS image sensors [18] - Weichai Lovol Smart Agriculture Technology Co., Ltd. is a leading provider of smart agricultural solutions in China [19] - PPIO is an independent distributed cloud computing service provider [20] - Xiangkang Holdings is a major technical apparel manufacturer for high-end brands [22] Group 2: Companies Passing Hearings - Four companies passed the listing hearing this week, including Fuwai Group, which is a pan-Asian life insurance company with projected insurance revenue growth [24] - Fengcai Technology focuses on chip design for BLDC motor control, ranking sixth in the Chinese market [25] - Xunzhong Communication Technology Co., Ltd. is the third-largest cloud communication service provider in China [26] - Cloudbreak Pharma Inc. is a clinical-stage ophthalmic biotech company with two core products [27] Group 3: Recent IPOs - Haitan Flavor Industry (03288.HK) raised approximately HKD 10.1 billion in its IPO, with a slight decline in stock price post-listing [28] - Sanhua Intelligent (02050.HK) had a strong subscription rate for its IPO [29] - Baize Medical (02609.HK) and other companies also reported significant subscription rates for their IPOs [30][31][32][33]

Group 1: Recent IPOs - Haitian Flavor Industry, a leading condiment company from Foshan, officially listed on the Hong Kong Stock Exchange, raising approximately HKD 10.129 billion with a market capitalization of HKD 212.3 billion [1] - Black Eye Technology, a mobile game developer from Hong Kong, filed for an IPO on NASDAQ, planning to issue 1.5 million shares to raise about USD 6 million [2] - Jiamei New Materials, a nylon product manufacturer from Fuzhou, submitted an IPO application to NASDAQ, aiming to raise approximately USD 6 million [3] - Hope Sea Inc, a comprehensive supply chain solutions provider from Shenzhen, filed for an IPO on the Hong Kong Stock Exchange, focusing on cross-border supply chain solutions for electronic products [4] - Wolong Nuclear Materials, a high-speed copper cable manufacturer from Shenzhen, submitted an IPO application for "A+H" shares on the Hong Kong Stock Exchange [5] - Banou, a hot pot enterprise from Beijing, filed for an IPO on the Hong Kong Stock Exchange, claiming to be the largest brand in China's quality hot pot market with a 3.1% market share [6] - Xin'ao Co., a private natural gas company from Langfang, submitted an IPO application to the Hong Kong Stock Exchange, leveraging over 30 years of operational experience [7] - Anmai Biotech, a Shanghai-based biotechnology company, filed for an IPO on the Hong Kong Stock Exchange, focusing on T-cell connectors for cancer and autoimmune disease treatments [8] - Vision Electronics, a commercial display equipment company from Guangzhou, submitted an IPO application for "A+H" shares on the Hong Kong Stock Exchange [9] - Haizhi Technology, an AI company from Beijing, filed for an IPO on the Hong Kong Stock Exchange, ranking fifth among industrial AI providers in China by revenue [10] - Diguantong, a fintech platform from Macau, filed for an IPO on the Hong Kong Stock Exchange, aiming to connect global capital with China's micro-economy [11] - Yuxin Technology, a fintech solution provider from Beijing, submitted an IPO application to the Hong Kong Stock Exchange, focusing on full-stack technology solutions for financial institutions [12] - Zhaowei Electromechanical, a provider of integrated micro-drive systems from Shenzhen, filed for an IPO on the Hong Kong Stock Exchange [13] - Meige Intelligent, a wireless communication module provider from Shenzhen, submitted an IPO application to the Hong Kong Stock Exchange, ranking fourth globally in wireless communication module revenue [14] - Jiyi Technology, a cross-border e-commerce service provider from Suzhou, filed for an IPO on the Hong Kong Stock Exchange, leading in cross-border e-commerce operations in China [15] Group 2: Upcoming IPOs - Xiangjiang Electric, a home appliance manufacturer, is set to launch an IPO from June 17 to June 20, aiming to raise approximately HKD 212 million [16] - Cao Cao Mobility, a travel technology platform, plans to launch an IPO from June 17 to June 20, targeting to raise about HKD 1.853 billion [17] - Saint Bella, a comprehensive home care brand group, will conduct an IPO from June 18 to June 23, aiming to raise around HKD 628 million [18] - Zhou Li Fu, a jewelry company, is set to launch an IPO from June 18 to June 23, targeting to raise approximately HKD 1.123 billion [19] - Yingtong Holdings, a perfume brand management company, plans to conduct an IPO from June 18 to June 23, aiming to raise about HKD 1.127 billion [20] Group 3: Regulatory Approvals - Ten companies, including Tianyu Semiconductor and Shuangdeng Group, received approval from the China Securities Regulatory Commission for overseas listings and "full circulation" of unlisted shares [21]

Core Viewpoint - BioNTech is scaling back its CAR-T therapy operations in response to underwhelming results from early cancer trials, leading to layoffs at its Maryland facility [1] Group 1 - BioNTech plans to reduce the production scale of its CAR-T therapy at its first U.S. facility due to disappointing trial outcomes [1] - The company will lay off 63 employees, primarily from the cell therapy technical operations team at its Gaithersburg, Maryland site [1] - The layoffs are expected to take place by the end of summer this year [1]

Core Insights - The Chinese biotechnology industry is expected to continue its recovery in the second half of 2025, driven by a resurgence in the Hong Kong IPO market and improved earnings outlook for biotech companies [3][15] - Key focus areas include the anticipated approval of new drugs, significant pipeline data releases, and increased merger and acquisition (M&A) activities, particularly related to the PD-1/VEGF pathways [3][15] Group 1: Market Trends - The Hong Kong IPO market is showing signs of recovery, with Hengrui's IPO raising HKD 9.8 billion, marking the largest IPO in the Hong Kong pharmaceutical sector in five years [15] - Investor interest in the biotechnology sector remains high, as evidenced by the successful listing of antibody-drug conjugate pioneer, InnoCare, which saw its share price double on the first trading day [15] - M&A activities are expected to surge in 2025, particularly for companies involved in the PD-1/VEGF pathway, following positive data reported at the ASCO conference [5][15] Group 2: Company Performance and Projections - Chinese biotech companies are reaching a pivotal point of profitability, with Innovent Biologics expected to turn profitable in 2024, supported by the launch of its obesity drug and positive data from IBI 363 at ASCO [6] - BeiGene achieved breakeven in Q1 and is positioned to become a major player in global oncology, although its sales growth from 2025 to 2028 is projected to be below peers [6] - Companies like Akeso and Zai Lab are also expected to achieve profitability by 2025, despite facing valuation pressures due to tariff uncertainties [6] Group 3: Pipeline Developments - Innovent's obesity drug, Mazdutide, is anticipated to launch in China in early 2025, which could attract significant investor interest [9] - BeiGene's Sonrotoclax is expected to file for approval in China for treating relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma by mid-2026 [9] - Akeso is advancing multiple drugs through the pipeline, with filings for Cadonilimab and Ivonescimab expected in the second half of 2025 [10][13] Group 4: Valuation Metrics - The enterprise value/sales ratios for several Chinese biotech companies indicate varying growth expectations, with Sichuan Kelun-Biotech showing a high ratio of 35.5x and a projected sales CAGR of 54% from 2025 to 2028 [8] - The average enterprise value/sales ratio for Chinese peers stands at 13.0x, with a median of 11.8x, reflecting the competitive landscape within the industry [8]

Core Viewpoint - Anmai Biotech Co., Ltd. is preparing for an IPO on the Hong Kong Stock Exchange, focusing on developing T-cell engagers for cancer and autoimmune diseases, with significant global partnerships and a strong clinical pipeline [1][2][5]. Group 1: Company Overview - Anmai Biotech was established in 2015 and is a clinical-stage biotechnology company specializing in T-cell engagers for various cancers and autoimmune diseases [2]. - The company has received investments from notable institutions including CITIC Capital, Decheng Capital, and others [6]. Group 2: Clinical Pipeline - Anmai Biotech's oncology pipeline includes three clinical-stage candidates: EMB-01 for colorectal cancer, EMB-06 for multiple myeloma, and EMB-07 for lymphoma and solid tumors [3][4]. - EMB-01 is the world's first EGFR/cMET bispecific antibody to enter Phase II trials for colorectal cancer, with a focus on metastatic colorectal cancer [4]. Group 3: Market Position and Partnerships - As of the end of 2023, Anmai Biotech has established multiple global licensing collaborations with a total transaction value exceeding $2.1 billion, ranking second globally in the T-cell engager field [5]. - The company aims to use the net proceeds from the IPO to fund ongoing and planned clinical trials for its core product EMB-01 and other pipeline assets [7].

Core Insights - Company is a clinical-stage biotechnology firm focused on developing T-cell engagers for cancer and autoimmune diseases, with a pipeline that includes three clinical candidates and several preclinical candidates [3][4] Pipeline Overview - Oncology pipeline includes three clinical-stage candidates: EMB-01 targeting EGFR/cMET for colorectal cancer, EMB-06 targeting BCMA/CD3 for multiple myeloma, and EMB-07 targeting ROR1/CD3 for lymphoma and solid tumors [3] - Immunology pipeline features EMB-06 as a key clinical candidate, along with two preclinical candidates [3] Technology Platforms - Company has developed three proprietary technology platforms: FIT-Ig, MAT-Fab, and T-FIT, aimed at overcoming limitations in traditional bispecific antibody development [4] Strategic Collaborations - Company has established multiple global licensing collaborations with a total transaction value exceeding $2.1 billion, ranking second globally in the T-cell engager field [4] - Collaboration with Almirall for the development of bispecific antibodies using the FIT-Ig platform, with Almirall exercising options on some FIT-Ig molecules [4] - Partnership with Vignette Bio, now acquired by Candid, to advance EMB-06 development outside of China, with a potential total transaction value of $635 million [5] Financial Performance - Company reported revenue of approximately RMB 459 million for the fiscal year 2024, with losses of RMB 595 million and RMB 48 million for the fiscal years 2023 and 2024, respectively [7][8] - Key financial metrics include a gross profit of RMB 456 million and significant R&D expenditures [8]

6月16日，一家在美上市的中概股脑再生科技（RGC.US）引发市场高度关注。其股价单日涨幅达到283.12%，盘中出现多次熔断。截至当日收盘，脑再生科 技股价报每股60美元，市值飙升至296.69亿美元，创历史新高。 脑再生科技股价异动始于今年4月30日。当天，其开盘价仅为0.832美元，一度大涨逾98%。此后，其股价持续上扬，直至6月16日的惊人涨幅。按年初0.13美 元/股的股价计算，今年以来，脑再生科技股价累计涨幅达到46000%。 消息面上，6月16日，脑再生科技此前公布的38对1的股票拆分正式开始交易，拆分以股票红利形式进行（记录日登记在册的股东每持有1股可获发37股额外 股份）。6月17日，脑再生科技也在官网发布了该信息。 每经记者｜黄婉银 每经编辑｜张海妮 区一佳是投行出身，涉足房地产、科技和生物技术等领域的投资。区一佳的父亲是香港一名中医师，脑再生科技称其在行医期间治疗了许多患有ADHD和 ASD的儿童。而在开始中医临床实践之前，区一佳的父亲还在美国加利福尼亚州创立了一家房地产公司。 2018年，脑再生科技与区一佳的父亲签订了战略合作协议，其治疗ADHD和ASD的方法主要来自一个基本中药配方， ...